轩竹生物(02575.HK)安奈拉唑钠肠溶片获国家药监局受理RE新适应症申请

阿斯达克财经
Jun 30

轩竹生物(02575.HK) 公布,公司自主研发的国家1类创新药安奈拉唑钠肠溶片(商品名:安久卫)用于治疗成人反流性食管炎(RE)的新适应症上市申请于近日获国家药品监督管理局正式受理。RE适应症是安奈拉唑钠继十二指肠溃疡后第二个递交上市申请的适应症。(sl/a)(港股报价延迟最少十五分钟。沽空资料截至 2026-06-29 16:25。)AASTOCKS新闻

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10